Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Immunogen

His-tagged, full-length recombinant human Cyclin D3.

Physical form

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Reconstitution

Please refer to lot specific datasheet.

Specificity

Clone DCS-22 is a mouse monoclonal antibody that detects human Cyclin D3. It targets an epitope within 20 amino acids from the C-terminal region.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Target description

G1/S-specific cyclin-D3 (UniProt: P30281; also known as Cyclin D3) is encoded by the CCND3 gene (Gene ID: 896) in human. Cyclin D3 is one of the most widely and ubiquitously expressed D-type cyclin. It serves as a growth factor sensor and a regulatory component of the cyclin D3-CDK4 complex that phosphorylates and inhibits members of the retinoblastoma protein family, including RB1, and regulates the cell-cycle during G1/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G1 phase. Cyclin D-CDK4 complexes are major integrators of various mitogenic and antimitogenic signals. They accumulate at the nuclear membrane and are then translocated to the nucleus through interaction with KIP/CIP family members. Cyclin D3 is also shown to be essential for cell proliferation stimulated by TSH and TSH induces the nuclear translocation of D3- CDK4 complex. TGF-beta is reported to block TSH induced nuclear translocation of D3-CDK4 complex. Elevated levels of cyclin D3 have been reported in breast cancer and are indicator of poor survival. Four isoforms of cyclin D3 have been described that are produced by alternative splicing. (Ref.: Bartkova, J., et al. (1998). Oncogene. 17 (); 1027-1037; Van Keymeulen, A., et al. (1999). Oncogene. 18, 7351-7359; Depoortere, F., et al. (2000). Mol. Biol. Cell. 11; 1061-1076; Chi, Y., et al. (2015). Cancer Cell Int. 15; Article number: 89).